Sigrid Therapeutics

About Sigrid Therapeutics

Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics. This gel-based solution aims to prevent the progression to type 2 diabetes, addressing the rising global prevalence of lifestyle diseases linked to poor diet and inactivity.

```xml <problem> Globally, a significant portion of deaths are attributed to lifestyle diseases like obesity, type 2 diabetes, and heart disease, often stemming from poor diet and physical inactivity. Prediabetes, a condition of elevated blood sugar, often progresses to type 2 diabetes if left unmanaged. Currently, there are limited treatment options specifically designed for individuals with prediabetes. </problem> <solution> Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device formulated as a consumer-friendly gel, designed to reduce blood sugar levels in individuals with prediabetes and newly diagnosed type 2 diabetes. SiPore21® is designed to be easily consumed. By lowering blood sugar, SiPore21® aims to prevent or delay the progression from prediabetes to type 2 diabetes. The product candidate originates from research conducted at Stockholm University and the Karolinska Institute. </solution> <features> - Orally ingested gel formulation for ease of use. - Designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics. - Aims to prevent the progression of prediabetes to type 2 diabetes. </features> <target_audience> The primary target audience includes individuals with prediabetes and those newly diagnosed with type 2 diabetes. </target_audience> ```

What does Sigrid Therapeutics do?

Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics. This gel-based solution aims to prevent the progression to type 2 diabetes, addressing the rising global prevalence of lifestyle diseases linked to poor diet and inactivity.

When was Sigrid Therapeutics founded?

Sigrid Therapeutics was founded in 2014.

Founded
2014
Employees
20 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Start Searching

Sigrid Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics. This gel-based solution aims to prevent the progression to type 2 diabetes, addressing the rising global prevalence of lifestyle diseases linked to poor diet and inactivity.

sigridthx.com5K+
Founded 2014

Funding

No funding information available.

Team (20+)

No team information available.

Company Description

Problem

Globally, a significant portion of deaths are attributed to lifestyle diseases like obesity, type 2 diabetes, and heart disease, often stemming from poor diet and physical inactivity. Prediabetes, a condition of elevated blood sugar, often progresses to type 2 diabetes if left unmanaged. Currently, there are limited treatment options specifically designed for individuals with prediabetes.

Solution

Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device formulated as a consumer-friendly gel, designed to reduce blood sugar levels in individuals with prediabetes and newly diagnosed type 2 diabetes. SiPore21® is designed to be easily consumed. By lowering blood sugar, SiPore21® aims to prevent or delay the progression from prediabetes to type 2 diabetes. The product candidate originates from research conducted at Stockholm University and the Karolinska Institute.

Features

Orally ingested gel formulation for ease of use.

Designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.

Aims to prevent the progression of prediabetes to type 2 diabetes.

Target Audience

The primary target audience includes individuals with prediabetes and those newly diagnosed with type 2 diabetes.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.